This study is the first to link p53 pathway-related miRNAs to the risk of HF after AMI, but it has notable limitations: only 21 HF patients were included, the impact of treatments such as statins on miRNA levels was not considered, and the consistency of these three miRNAs’ expression in HF of other etiologies remains unclear, limiting their application as broad-spectrum biomarkers. This evidence concerns the gene TP53 and hydrops fetalis.